COLLAGEN MEDICAL LLC

Belmont, MA · Medtech · Private

PET imaging probe (68Ga-CBP8) targeting type 1 collagen for non-invasive detection and quantification of radiation-induced lung injury

cmed.cc →
Grants
$15M
23 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
$2.5M
2 awards · Health and Human S
#186 of 4531 in medtech
Patents
9
1 granted · 8 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Health and Human Services · Igf::ot::igf Mr Contrast Agent To Quantify Myocardial Fibrosis - SBIR Topic 072 - Phase I$915,741
Federal contractDepartment of Health and Human Services · Igf::ot::igf SBIR Topic 85 To Support The Development Of Target Specific Molecular Imaging Agents In Combination With Existing Imaging Modalities To Detect High Risk Atherosclerotic Plaque.$1,591,491
Federal grantDepartment of Health and Human Services · Phase II · CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging$427,371
Federal grantDepartment of Health and Human Services · Phase II · CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging$857,523
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Fibrin Targeted Cancer Therapy$242,178
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Fibrin Targeted Cancer Therapy$242,178
Federal grantDepartment of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer$300,000
Federal grantDepartment of Health and Human Services · Phase II · CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging$430,152
Federal grantDepartment of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer$997,515
Federal grantDepartment of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer$1,002,483
Federal grantDepartment of Health and Human Services · Phase II · Targeted Imaging of Fibrosis in the Left Atrium$295,301
Federal grantDepartment of Health and Human Services · Phase II · Molecular MR Imaging of the Desmoplastic Response in Pancreatic Cancer$209,717
Federal grantDepartment of Health and Human Services · Phase I · Magnetic Particle Detection Test for Vulnerable Carotid Plaque$299,849
Federal grantDepartment of Health and Human Services · Phase II · PET imaging of radiation induced lung injury$399,990
Federal grantDepartment of Health and Human Services · Phase II · Molecular Imaging Agent to Detect Thrombus$496,849
Federal grantDepartment of Health and Human Services · Phase II · Targeted Imaging of Fibrosis in the Left Atrium$766,000
Federal grantDepartment of Health and Human Services · Phase I · New class of collagen-targeted contrast agents for Magnetic Resonance Imaging$287,065
Federal grantDepartment of Health and Human Services · Phase I · New class of collagen-targeted contrast agents for Magnetic Resonance Imaging$287,065
Federal grantDepartment of Health and Human Services · Phase II · Targeted Imaging of Fibrosis in the Left Atrium$725,517
Federal grantDepartment of Health and Human Services · Phase II · PET imaging of radiation induced lung injury$1,996,724
Federal grantDepartment of Health and Human Services · Phase II · PET imaging of radiation induced lung injury$1,191,390
Federal grantDepartment of Health and Human Services · Phase II · PET imaging of radiation induced lung injury$805,334
Federal grantDepartment of Health and Human Services · Phase II · Theranostic for gastric cancer$395,933
Federal grantDepartment of Health and Human Services · Phase II · Theranostic for gastric cancer$885,123
Federal grantDepartment of Health and Human Services · Phase II · Theranostic for gastric cancer$1,065,500
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
183LUMOSTECH, INC.$2.7M—
184Sword Health$2.6M—
185PACT & HEALTH LLC$2.6M—
186COLLAGEN MEDICAL LLC$2.5M—
187DILON TECHNOLOGIES INC$2.5M$22M
188Wenzel Spine, Inc.$2.5M$4.9M
189MICROMICS TECHNOLOGIES LLC$2.5M—

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 9
  • Collagen Imaging Compositionsgranted
  • Collagen Imaging Compostionsapplication
  • Collagen Imaging Compositionsapplication
  • Collagen Imaging Compostionsapplication
  • Collagen Imaging Compostionsapplication
  • Contrast Agents For Collagen And Fibrin Imagingapplication
  • Collagen Imaging Compositionsapplication
  • Fibrin-binding Compounds For Imaging And Treatmentapplication
  • Fibrin-binding Compounds For Imaging And Treatmentapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.